The global demand for Malignant Pleural Mesothelioma Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Pleural Mesothelioma is a malignant tumour which develops in the lining of the pleura I. E. The lungs. This tumour is caused by continuous exposure to asbestos fibres. Prolonged exposure to asbestos causes inflammation of the pleura which gradually develops into a tumour. This tumour can develop if a person is exposed to asbestos for 10-50 years.Among all the types of Mesothelioma, this is the most common type of tumour. The symptoms of this disease are similar to any respiratory disease along with the symptoms of cancer. This tumour can be detected using scans, biopsy and thoracoscopy. If detected at the later stages the life expectancy can be between 6-12 months. The usual treatment methods involve surgery, chemotherapy and radiation with the removal of a lung in worst-case. This is an incurable disease but emerging clinical trials can improve a patient's life expectancy.
The market of malignant pleural Mesothelioma is expected to grow due to the increase in the investment in construction sectors. Asbestos exposure to the workers on the construction site such as plumbers, electricians etc. can lead to such diseases. The increase in the commercial production of asbestos and asbestos-based consumer products can boost the growth of this market. The rise in geriatric population can as well fuel this market since the risk of this disease is higher among the old and can as well affect the family members of people in close contact with asbestos. This market will see a peak during COVID-19 times due to increase in infrastructural development to enable handling the large volume of patients in certain geographical areas. The main challenge faced by this market will be stringent rules put forth by the government for the asbestos industry owing to its carcinogenic effect.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of malignant pleural mesothelioma.
The entire malignant pleural mesothelioma market has been sub-categorized into drug type, route of administration and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Drug Type
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Oncology Centers
This section covers regional segmentation which accentuates on current and future demand for malignant pleural mesothelioma market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Malignant Pleural Mesothelioma Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the malignant pleural mesothelioma market include AstraZeneca Plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, BoehringerIngelheim GmbH, Mylan N.V., Others. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.